AMO acquires OptiMedica for laser cataract surgery

Article

Abbott Medical Optics (AMO) has announced the acquisition of OptiMedica, enabling expansion into the laser cataract surgery market.

Abbott Medical Optics (AMO) has announced the acquisition of OptiMedica, enabling expansion into the laser cataract surgery market.

The company will acquire OptiMedica for $250 million plus additional payments totalling almost $150 million. OptiMedica will allow AMO to access the Catalys Precision Laser System, which is designed to replace some of the technical demanding manual steps in cataract surgery.

The precise, computer-guided femtosecond laser system can be used to perform capsulotomies, phacofragmentation and incisions for ocular surgery. Catalys has receieved the CE Mark in Europe and approval from the FDA.

Murthy Simhambhatia, senior vice president at AMO, commented, “The acquisition of OptiMedica will provide Abbott with an entry point into the rapidly developing laser cataract surgery market. The Catalys laser system provides physicians with a state-of-the-art, computer-guided alternative in treating patients suffering from cataracts.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.